United Kingdom (UK)
Recombinant monoclonal antibody to CD80. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody IDEC-114 (Galiximab).
UniProt Accession Number of Target Protein: P33681
Alternative Name(s) of Target: B7-1; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7
Immunogen: Galiximab was prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)
Specificity: Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to CD80. CD80 is a surface glycoprotein and a member of the B7 family of costimulatory molecules. CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed consitutively on various subtypes of B-cell lymphomas.
Application Notes: Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-κB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximb affects CD28 and CD152 interactions with CD80. This antibody can also be used for FC, WB, ELISA, IP and IHC.
Antibody first published in:
Vinjamaram et al. The use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2008 Oct;8(5):277-82 PMID:18854281
Note on publication:
Describes clinical studies where B-Cell Lymphomas in NHL patients are targeted
with Galiximab.
Immunofluorescence staining of fixed Daudi cells with anti-CD80 antibody IDEC-114 (Galiximab) (Ab00736) Immunofluorescence analysis of paraformaldehyde fixed Daudi cells on Shi-fix™ coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of IDEC-114 (Galiximab) (Ab00736-23.0) at 10 µg/ml for 1h followed by Alexa Fluor® 488 secondary antibody (1 µg/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Ab00736-23.0, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody (Ab102-23.0) followed by Alexa Fluor® 488 secondary antibody.